PTC Therapeutics paid $225 million to cancel Censa sepiapterin sales payments
On August 5, 2025, PTC Therapeutics entered a Rights Satisfaction Agreement under which former Censa Pharmaceuticals securityholders gave up their rights to payments based on sepiapterin net sales. The company paid about $225 million in cash at closing and may owe up to $500 million more in milestone payments. Other obligations under the 2020 Merger Agreement remain in effect.
Key points
- At closing, PTC paid about $225.0 million in cash to participating former Censa securityholders, who held about 90% of Censa's equity.
- Participants forfeited net sales payments of 8% on sales up to $250.0 million, 10% on sales from $250.0 million to $500.0 million, and 12% on sales above $500.0 million.
- Additional milestone payments of about $90.0 million each, up to $500.0 million in total, are tied to aggregate net sales thresholds from $3.0 billion to $11.0 billion.
- The agreement was signed and closed simultaneously, and the full text will be filed with the Form 10-Q for the quarter ending September 30, 2025.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.